About US
Contact us
-
Head of Indian pricing authority pushed out after price hikesThe head ofIndia's National Pharmaceutical Pricing Authority was removed from the job just a week after his agency allowed the prices of 509 essential drugs to increase by 3.8%. But Chairman Injeta Sr2015/4/10
-
Natco brings its scrappy style to U.S. with Copaxone, Revlimid knockoffsGenerics playerNatco Pharmahas already made plenty of waves in the Indian pharma market with cheaper versions of blockbuster meds, playing by a patent challenge strategy that's ignited the ire of more2015/4/10
-
Roche nabs EU approval for Avastin for cervical cancerRoche's ($RHHBY)Avastinhas been on the market for more than a decade and boasts a long list of valuable approvals. But Roche is not sitting back the status quo, and continues to submit the drug for ne2015/4/9
-
Actavis, Ironwood mount second DTC push for GI med LinzessWith Actavis ($ACT) and Ironwood's ($IRWD) first DTC campaign for GI med Linzess, the goal was to help patients identify irritable bowel syndrome with constipation and chronic idiopathic constipation2015/4/9
-
Should 500K more young people be on statins? Guidelines say yes, JAMA reportsIf physicians followed new cholesterol guidelines for statin use, almost half a million young people in the U.S. would be prescribed a statin, aJAMA Pediatricsstudy concludes. Some 483,500 people aged2015/4/8
-
Shire could use boost from adult ADHD med to hit $10B goalShire ($SHPG) has said it's targeting $10 billion in sales by 2020, with $3 billion of that coming from its current pipeline. Now, it looks like anADHDproduct waiting in the wings could be ready in ti2015/4/8
-
Shire's Lialda, Gattex are hedge funder's latest patent targetsHedge fund manager Kyle Bass has struck out at drug patents once again. Just weeks after challenging two patents on an Acorda Therapeutics ($ACOR) drug, Bass asked the U.S. Patent and Trademark Office2015/4/7
-
J&J, Novartis lead pharma companies by market capWhich Big Pharma companies have the biggest market caps in the industry? TheMotley Foolhas a breakdown of the top 10, but we'll give you a hint: The list begins with Johnson & Johnson ($JNJ) and N2015/4/7
-
GSK shingles shot might trump Merck's Zostavax, analysts sayThough GlaxoSmithKline ($GSK) is still waiting on late-stage results from itsshinglesvaccine, HZ/su, Cowen & Co. analysts say the GSK shot may just be better than Merck'sZostavax. The deciding fac2015/4/3
-
Pfizer shutters vaccine sales business in China after Prevenar setbackAs it beefs up its vaccines business, Pfizer's ($PFE) looking to bolster revenue from the top-sellingPrevenarfamily of shots. But on that front, it's come up against a roadblock inChina--and so it's s2015/4/3